These data are consistent with findings from preclinical oral bioavailability studies of picoplatin. The company also announced findings from a preclinical study demonstrating that picoplatin retains its activity in small cell lung cancer (SCLC) cell lines made resistant by treatment with cisplatin, carboplatin or oxaliplatin.
Additional results from the phase I study suggest no drug accumulation between dosing cycles. All doses of the investigational drug were well tolerated. No serious adverse events related to treatment were observed following oral dosing.
Robert De Jager, chief medical officer of Poniard, said: “The data from our ongoing clinical study supports further development of an oral formulation of picoplatin. The data supports the possible use of picoplatin in tumors with acquired platinum resistance resulting from previous treatment with cisplatin, carboplatin or oxaliplatin. The use of platinum-resistant biomarkers may help to identify those patients who would most benefit from picoplatin treatment.”